Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor-Reference-Cited by-同舟云学术

Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor

Published:2019-12-01 Issue:8 Volume:17 Page:364-386
ISSN:1540-658X
Container-title:ASSAY and Drug Development Technologies
language:en
Short-container-title:ASSAY and Drug Development Technologies

Author:

Fancher Ashley T.¹,Hua Yun¹,Strock Christopher J.²,Johnston Paul A.¹³

Affiliation:

1. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.

2. Cyprotex US, Watertown, Massachusetts.

3. Head and Neck Cancer, and Skin Cancer Specialized Programs of Research Excellence, University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania.

Publisher

Mary Ann Liebert Inc

Subject

Drug Discovery,Molecular Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/adt.2019.940

Reference77 articles.

1. Cancer statistics, 2018

2. Characterising the castration-resistant prostate cancer population: a systematic review

3. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hydropathic AF‐2 variants in the androgen receptor gene among androgen insensitivity patients;Andrology;2024-06-26

2. Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation–Drug leads for metastatic castration resistant prostate cancer;SLAS Discovery;2023-10

3. Current and emerging approaches to noncompetitive AR inhibition;Medicinal Research Reviews;2023-04-16

4. Mild Androgen Insensitivity Syndrome: The Current Landscape;Endocrine Practice;2022-09

5. The Role of Androgens and Androgen Receptor in Human Bladder Cancer;Biomolecules;2021-04-18